Full Text View
Tabular View
Study Results
Related Studies
Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC
This study is ongoing, but not recruiting participants.
Study NCT00709761   Information provided by GlaxoSmithKline

First Received on July 1, 2008.   Last Updated on January 21, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Neoplasms, Breast
Additional conditions recognized in this trial
Breast Neoplasms
Neoplasms
More general conditions related to this trial
Breast Diseases
Neoplasms by Site
Skin Diseases
Interventions listed in this trial
Lapatinib/nab-Paclitaxel
Additional drug interventions recognized in this trial
Lapatinib
Paclitaxel
More general drug interventions related to this trial
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Enzyme Inhibitors
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
GlaxoSmithKline


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services